AstraZeneca PLC (AZN)
| Market Cap | 287.99B |
| Revenue (ttm) | 58.13B |
| Net Income (ttm) | 9.40B |
| Shares Out | 1.55B |
| EPS (ttm) | 6.02 |
| PE Ratio | 15.51 |
| Forward PE | 19.79 |
| Dividend | $1.54 (1.65%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 4,656,384 |
| Open | 93.00 |
| Previous Close | 93.32 |
| Day's Range | 92.84 - 94.02 |
| 52-Week Range | 61.24 - 94.02 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Nov 6, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from ...
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discover...
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
Why AstraZeneca Stock Bumped Higher Today
The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland.
AstraZeneca to invest $2 billion as part of US manufacturing push
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabil...
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its ...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines
London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker As...
AstraZeneca hits record high, cements lead as UK's biggest stock
Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
Why AstraZeneca Stock Was a Winner Today
The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well ...
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulat...
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first...
Why AstraZeneca Stock Topped the Market on Thursday
The global pharmaceutical giant posted some impressive growth numbers in its latest earnings release. It also crushed analyst estimates for profitability.
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
AstraZeneca PLC ( AZN) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CF...
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EP...
AstraZeneca's 9M and Q3 2025 Financial Results
CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release.
AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal
The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.
AstraZeneca beats third-quarter revenue and profit expectations
AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its fu...
AstraZeneca wins shareholder backing for NYSE listing in US pivot
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.